A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group, Pivotal Trial to Assess the Efficacy and Safety of Sonlicromanol in Adult Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Variant
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Sonlicromanol (Primary)
- Indications Mitochondrial disorders
- Focus Registrational; Therapeutic Use
- Acronyms KHENERFIN study
- Sponsors Khondrion
Most Recent Events
- 04 Dec 2025 Planned number of patients changed from 150 to 220.
- 04 Dec 2025 Planned End Date changed from 2 Jan 2028 to 2 Jul 2028.
- 04 Dec 2025 Planned primary completion date changed from 2 Jan 2028 to 2 Jul 2028.